Gogolox (Ambroxol Hydrochloride)

Gogolox is indicated for use in respiratory conditions where thick or tenacious mucus impairs airway clearance.

• Cough associated with acute upper or lower respiratory tract infections.
• Facilitation of mucus clearance in chronic bronchitis.
• Adjunct therapy for patients with asthma experiencing productive cough.
• Supportive treatment in COPD exacerbations with increased sputum viscosity.
• Management of mucus retention following inhalation injuries.

The safety profile of Ambroxol Hydrochloride, the active component of Gogolox, includes both frequent and rare adverse events.

Common

• Mild gastrointestinal discomfort such as nausea or dyspepsia.
• Transient skin rash or pruritus.
• Taste alteration or mild oral irritation.
• Headache.

Serious

• Allergic reactions including angioedema or anaphylaxis.
• Severe skin reactions such as Stevens‑Johnson syndrome.
• Hepatic enzyme elevation in susceptible individuals.

When considering Gogolox, healthcare providers should evaluate several precautionary factors to ensure safe use.

• Assess for known hypersensitivity to Ambroxol or related compounds.
• Use cautiously in patients with hepatic impairment.
• Monitor renal function in individuals with severe kidney disease.
• Pregnancy and lactation status should be reviewed, as safety data are limited.
• Avoid use in children under the age specified by local regulations.
• Consider potential interactions with other mucolytics or expectorants.

Gogolox may interact with other medicines; understanding these interactions helps minimize adverse effects.

Avoid

• Concurrent use with other mucolytic agents such as carbocisteine or N‑acetylcysteine.
• Co‑administration with drugs that may cause bronchospasm in susceptible patients.

Use with caution

• Anticoagulants, as Ambroxol may enhance bleeding risk.
• Bronchodilators, to monitor for additive respiratory effects.
• Antihistamines, due to possible increased sedation.